番茄社区

Meeting Coverage >

ASH: Hematology

Completely Oral Regimen Effective, Feasible in APL

97% of patients alive and relapse-free at 3 years

Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin's

3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab

New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT

Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk

'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL

Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease

C3 Pathway Inhibitor May Change Practice for Paroxysmal Nocturnal Hemoglobinuria

Iptacopan improved hemoglobin without transfusion versus current standard of care

High-Dose Chemo, ASCT Improves Survival in Primary CNS Lymphoma

European trial is "practice-changing as of today," says U.S. expert

Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibody

Most complete responses lasted 24 months or longer after limited-duration glofitamab

Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL

Phase III study showed 58% reduction in the risk of death versus chemo alone

Pediatric Hodgkin Lymphoma Survivors Experience Accelerated Epigenetic Aging

Data from St. Jude cohort show higher rates of neurocognitive impairment

Heparin Fails to Stop Miscarriages in Women With Inherited Thrombophilia

No difference in live birth rates with or without blood thinner

Durable Platelet Response in Immune Thrombocytopenia With Efgartigimod

Glycoprotein receptor inhibitor produces four times as many responses as placebo

Black Patients Less Likely to Get Advanced Treatments for PE

Also less likely for patients on Medicare and Medicaid

AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT

Similar outcomes if patients went directly to transplant or received intensive salvage first

Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma

Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients

Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma

Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone

Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT

"We should eliminate these silly neutropenic diets," expert says

Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemia

OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy

Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL

Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease

Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma

Updated analysis confirms advantages of less aggressive approach to low-burden disease

Gene Therapy Resolves Severe Pain Events in Sickle Cell Disease

LentiGlobin also normalized hemoglobin and reduced hemolysis markers

Can Dasatinib Dose Be Halved in Low-Risk CML?

Lower dose associated with improved tolerability, similar responses in propensity score analysis

CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL

Patients, trial design, logistics among possible explanations for lack of EFS benefit

Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/B

Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors

R-CHOP Toppled in First-Line DLBCL Trial

Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity

Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL

One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate

尾-Thalassemia Patients Go Transfusion-Free With Gene Therapy

Treatment with beti-cel is "potentially curative" in this transfusion-dependent group

R2 Maintenance for Elderly MCL Patients Worth the Risk?

Longer PFS with addition of lenalidomide to rituximab, but also more toxicity

Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates

Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy

Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphoma

Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease

Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myeloma

Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity

CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma

Large increases in event-free survival with two CAR T-cell products in second line

Upfront IDH1 Inhibitor Triples Survival in Older AML

Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy

Non-Hodgkin Lymphoma: Bispecific Antibodies Impress in Refractory Disease

Odronextamab, epcoritamab surpass 90% response threshold in early trials

Chemo-Free Combo Boosts PFS in First-Line CLL

PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting

Novel Agent Active in Refractory CML

Asciminib doubles molecular response versus bosutinib after two or more prior lines of therapy

Gene Therapy Stops Bleeding in Hemophilia

Single injection had durable effectiveness, study showed

Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLL

DFS at 1 year reaches 95% in patients with undetectable MRD

CRISPR-Based Tx Offers Hope in Tough-to-Treat Blood Disorders

Success with investigational use of gene editing in sickle cell disease, beta-thalassemia

Blood Cancers and COVID-19: 'A Medically Vulnerable' Group

Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death

JAK Inhibitor Wins in Second-Line Chronic GVHD

Twice as many patients achieved a response at week 24

1